Paediatric abacavir–lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial-Reference-Cited by-同舟云学术

Paediatric abacavir–lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial

Published:2024-02 Issue:2 Volume:11 Page:e86-e95
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Bekker Adrie,Salvadori Nicolas,Rabie Helena,du Toit Samantha,Than-in-at Kanchana,Groenewald Marisa,Cressey Ratchada,Nielsen James,Capparelli Edmund V,Lallemant Marc,Cotton Mark F,Cressey Tim R

Publisher

Elsevier BV

Reference21 articles.

1. Early antiretroviral therapy and mortality among HIV-infected infants;Violari;N Engl J Med,2008

2. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach,2021

3. Single dose abacavir pharmacokinetics and safety in neonates exposed to human immunodeficiency virus (HIV);Bekker;Clin Infect Dis,2021

4. Impact of food administration on lopinavir-ritonavir bioequivalence studies;Ibarra;Eur J Pharm Sci,2012

5. Pharmacokinetics of two generic co-formulations of lopinavir/ritonavir for HIV-infected children: a pilot study of paediatric Lopimune versus the branded product in healthy adult volunteers;de Kanter;J Antimicrob Chemother,2010

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lamivudine dosing for preterm infants exposed to HIV: a population pharmacokinetic modelling and simulation study;Journal of Antimicrobial Chemotherapy;2024-08-02

2. A call to accelerate antiretroviral development for neonates;The Lancet HIV;2024-02